Literature DB >> 22028616

Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Amir A Jazaeri1, Jennifer L Bryant, Hong Park, Hui Li, Neetu Dahiya, Mark H Stoler, James Stuart Ferriss, Anindya Dutta.   

Abstract

Although controversial, recent studies suggest that serous ovarian carcinomas may arise from fallopian tube fimbria rather than ovarian surface epithelium. We developed an in vitro model for serous carcinogenesis in which primary human fallopian tube epithelial cells (FTECs) were exposed to potentially oncogenic molecular alterations delivered by retroviral vectors. To more closely mirror in vivo conditions, transformation of FTECs was driven by the positive selection of growth-promoting alterations rather antibiotic selection. Injection of the transformed FTEC lines in SCID mice resulted in xenografts with histologic and immunohistochemical features indistinguishable from poorly differentiated serous carcinomas. Transcriptional profiling revealed high similarity among the transformed and control FTEC lines and patient-derived serous ovarian carcinoma cells and was used to define a malignancy-related transcriptional signature. Oncogene-treated FTEC lines were serially analyzed using quantitative reverse transcription-polymerase chain reaction and immunoblot analysis to identify oncogenes whose expression was subject to positive selection. The combination of p53 and Rb inactivation (mediated by SV40 T antigen), hTERT expression, and oncogenic C-MYC and HRAS accumulation showed positive selection during transformation. Knockdown of each of these selected components resulted in significant growth inhibition of the transformed cell lines that correlated with p27 accumulation. The combination of SV40 T antigen and hTERT expression resulted in immortalized cells that were nontumorigenic in mice, whereas forced expression of a dominant-negative p53 isoform (p53DD) and hTERT resulted in senescence. Thus, our investigation supports the tubal origin of serous carcinoma and provides a dynamic model for studying early molecular alterations in serous carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028616      PMCID: PMC3201567          DOI: 10.1593/neo.11138

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  50 in total

1.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

2.  PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.

Authors:  Ayhan Ozcan; Steven S Shen; Candice Hamilton; Kundu Anjana; Donna Coffey; Bhuvaneswari Krishnan; Luan D Truong
Journal:  Mod Pathol       Date:  2011-02-11       Impact factor: 7.842

3.  Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.

Authors:  Fatima Laki; Youlia M Kirova; Pascale This; Corinne Plancher; Bernard Asselain; Xavier Sastre; Dominique Stoppa-Lyonnet; Remy Salmon
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

4.  Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.

Authors:  Annette Staebler; Bianca Karberg; Juliane Behm; Petra Kuhlmann; Ulrike Neubert; Hartmut Schmidt; Eberhard Korsching; Horst Bürger; Ralph Lelle; Ludwig Kiesel; Werner Böcker; Ie-Ming Shih; Olaf Buchweitz
Journal:  Genes Chromosomes Cancer       Date:  2006-10       Impact factor: 5.006

5.  Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.

Authors:  Michael J Callahan; Christopher P Crum; Fabiola Medeiros; David W Kindelberger; Julia A Elvin; Judy E Garber; Colleen M Feltmate; Ross S Berkowitz; Michael G Muto
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

6.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

Review 7.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

8.  Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

Authors:  Kristin K Deeb; Aleksandra M Michalowska; Cheol-Yong Yoon; Scott M Krummey; Mark J Hoenerhoff; Claudine Kavanaugh; Ming-Chung Li; Francesco J Demayo; Ilona Linnoila; Chu-Xia Deng; Eva Y-H P Lee; Daniel Medina; Joanna H Shih; Jeffrey E Green
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

Review 9.  DNA damage signalling guards against activated oncogenes and tumour progression.

Authors:  J Bartek; J Bartkova; J Lukas
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

10.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Authors:  Joshua Z Press; Alessandro De Luca; Niki Boyd; Sean Young; Armelle Troussard; Yolanda Ridge; Pardeep Kaurah; Steve E Kalloger; Katherine A Blood; Margaret Smith; Paul T Spellman; Yuker Wang; Dianne M Miller; Doug Horsman; Malek Faham; C Blake Gilks; Joe Gray; David G Huntsman
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

View more
  42 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 2.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

3.  Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models.

Authors:  Ruth Perets; Gregory A Wyant; Katherine W Muto; Jonathan G Bijron; Barish B Poole; Kenneth T Chin; Jin Yun H Chen; Anders W Ohman; Corey D Stepule; Soongu Kwak; Alison M Karst; Michelle S Hirsch; Sunita R Setlur; Christopher P Crum; Daniela M Dinulescu; Ronny Drapkin
Journal:  Cancer Cell       Date:  2013-12-09       Impact factor: 31.743

4.  Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.

Authors:  L Minig; S Cabrera; R Oliver; A Couso; M J Rubio; S Iacoponi; M B Martin-Salamanca; S Carballo-Rastrilla; J M Cádenas-Rebollo; A García-Garcia; B Gil-Ibáñez; M J Juan-Fita; M G Patrono
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

5.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

6.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

7.  Primary culture and immortalization of human fallopian tube secretory epithelial cells.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  Nat Protoc       Date:  2012-08-30       Impact factor: 13.491

8.  New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research.

Authors:  Mark E Sherman; Richard Guido; Nicolas Wentzensen; Hannah P Yang; Phuong L Mai; Mark H Greene
Journal:  Gynecol Oncol       Date:  2012-08-29       Impact factor: 5.482

9.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

10.  Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis.

Authors:  Priyanka Singh; Laura M Jenkins; Ben Horst; Victoria Alers; Shrikant Pradhan; Prabhjot Kaur; Tapasya Srivastava; Nadine Hempel; Balázs Győrffy; Eugenia V Broude; Nam Y Lee; Karthikeyan Mythreye
Journal:  Cancer Res       Date:  2018-03-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.